All In Biotech

Drug Trial Radar · NCT05496335

A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines

A Phase 1 Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) in Subjects for Treatment of Glabellar Lines

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Aug 30, 2022

Primary completion

May 30, 2023

Study completion May 30, 2023

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Aug 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective sequential administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) is in adult participants with moderate to severe GL. AGN-151586 is an investigational product being developed for the treatment of GL. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. One group will receive AGN-151586 followed by BOTOX and the other group will receive placebo followed by BOTOX. There is a 1 in 2 chance that participants will be assigned to placebo. Around 80 adult participants with moderate to severe GL will be enrolled in the study in approximately 10 sites around the United States. Participants will receive either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Eligible participants may then receive BOTOX injections on Day 30 and will be followed for up to 4 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Conditions

  • Glabellar Lines

Interventions

  • AGN-151586Drug

    Intramuscular Injection

  • BOTOXDrug

    Intramuscular Injection

  • PlaceboDrug

    Intramuscular Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants achieving "none" or "mild" on the Facial Wrinkle Scale (FWS) according to the investigator assessment of Glabellar Lines (GL) severity at maximum frownTime frame: At Day 60

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • The Eye Research Foundation /ID# 244430

    Newport Beach, California

  • Cosmetic Laser Dermatology /ID# 244425

    San Diego, California

  • AboutSkin Research, LLC /ID# 244416

    Greenwood Village, Colorado

  • Skin Research Institute LLC /ID# 244424

    Coral Gables, Florida

  • Skin and Cancer Associates, LLP /ID# 244415

    Miami, Florida

  • DeNova Research /ID# 244421

    Chicago, Illinois

  • Advanced Dermatology /ID# 244427

    Lincolnshire, Illinois

  • Laser and Skin Surgery Center of Indiana /ID# 244423

    Indianapolis, Indiana

  • Bellaire Dermatology Associates /ID# 244428

    Bellaire, Texas

  • Premier Clinical Research /ID# 244429

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.